Search research articles
Contact Us
Filters
Showing results (71-80 of 98) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas
Brigitte C Widemann, Wanda L Salzer, Robert J Arceci, et al.
The Oncologist
|
October 29, 2017
Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance
Laura B Ramsey, Frank M Balis, Maureen M O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2021
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Jennifer H Foster, Stephan D Voss, David C Hall, et al.
Leukemia & Lymphoma
|
December 16, 2006
Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P
Paul C Nathan, Trish Whitcomb, Pamela L Wolters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial
Susan M Blaney, Frank M Balis, Stacey Berg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2010
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer
Ronan J Kelly, Deborah Draper, Clara C Chen, et al.
Cancer Medicine
|
November 27, 2025
A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors
David S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
The Lancet. Oncology
|
April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P Mossé, Megan S Lim, Stephan D Voss, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 98) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2006
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas
Brigitte C Widemann, Wanda L Salzer, Robert J Arceci, et al.
The Oncologist
|
October 29, 2017
Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance
Laura B Ramsey, Frank M Balis, Maureen M O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 19, 2008
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
Elizabeth Fox, John M Maris, Brigitte C Widemann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2021
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912)
Jennifer H Foster, Stephan D Voss, David C Hall, et al.
Leukemia & Lymphoma
|
December 16, 2006
Very high-dose methotrexate (33.6 g/m(2)) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P
Paul C Nathan, Trish Whitcomb, Pamela L Wolters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 10, 2010
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors
Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2005
Intrathecal mafosfamide: a preclinical pharmacology and phase I trial
Susan M Blaney, Frank M Balis, Stacey Berg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2010
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer
Ronan J Kelly, Deborah Draper, Clara C Chen, et al.
Cancer Medicine
|
November 27, 2025
A Phase 1 Trial of Fimepinostat in Children and Adolescents With Relapsed and Refractory Solid and CNS Tumors
David S Shulman, Kieuhoa T Vo, Frank M Balis, et al.
The Lancet. Oncology
|
April 20, 2013
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P Mossé, Megan S Lim, Stephan D Voss, et al.
Page
of 10